38 results on '"Hurt, Aeron C"'
Search Results
2. Assessing the fitness of a dual-antiviral drug resistant human influenza virus in the ferret model.
- Author
-
Stannard, Harry L., Mifsud, Edin J., Wildum, Steffen, Brown, Sook Kwan, Koszalka, Paulina, Shishido, Takao, Kojima, Satoshi, Omoto, Shinya, Baba, Keiko, Kuhlbusch, Klaus, Hurt, Aeron C., and Barr, Ian G.
- Subjects
INFLUENZA A virus ,INFLUENZA viruses ,INFLUENZA ,INFECTIOUS disease transmission ,AIRBORNE infection ,FERRET ,ANTIVIRAL agents ,DRUG resistance - Abstract
Influenza antivirals are important tools in our fight against annual influenza epidemics and future influenza pandemics. Combinations of antivirals may reduce the likelihood of drug resistance and improve clinical outcomes. Previously, two hospitalised immunocompromised influenza patients, who received a combination of a neuraminidase inhibitor and baloxavir marboxil, shed influenza viruses resistant to both drugs. Here-in, the replicative fitness of one of these A(H1N1)pdm09 virus isolates with dual resistance mutations (NA-H275Y and PA-I38T) was similar to wild type virus (WT) in vitro, but reduced in the upper respiratory tracts of challenged ferrets. The dual-mutant virus transmitted well between ferrets in an airborne transmission model, but was outcompeted by the WT when the two viruses were co-administered. These results indicate the dual-mutant virus had a moderate loss of viral fitness compared to the WT virus, suggesting that while person-to-person transmission of the dual-resistant virus may be possible, widespread community transmission is unlikely. A clinical influenza isolate with dual antiviral resistant mutations displays a moderate loss of viral fitness in ferrets compared to wild-type virus, suggesting widespread community transmission of this dual mutant is unlikely. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Infection with different human influenza A subtypes affects the period of susceptibility to secondary bacterial infections in ferrets.
- Author
-
Mifsud, Edin J., Farrukee, Rubaiyea, Hurt, Aeron C., Reading, Patrick C., and Barr, Ian G.
- Subjects
INFLUENZA viruses ,PNEUMONIA ,PUBLIC health ,HOSPITAL care ,STREPTOCOCCUS pneumoniae - Abstract
It iswell-established that influenza virus infections predispose individuals to secondary bacterial infections (SBIs), which may result in a range of clinical outcomes from relatively mild (e.g. sinusitis and otitis media) to severe (e.g. pneumonia and septicaemia). The most common bacterial pathogen associated with SBI following influenza virus infections is Streptococcus pneumoniae (SPN). Of circulating human seasonal influenza viruses, influenza A viruses (IAV) of both the A(H1N1)pdm09 and A(H3N2) subtypes are associated with severe disease but have differing hospitalisation and complication rates. To study the interplay of these two IAV subtypes with SBI, we used a ferret model of influenza infection followed by secondary challenge with a clinical strain of SPN to determine the severity and the period of susceptibility for SBI. Ferrets challenged with SPN 5 days after infectionwith A(H3N2) or A(H1N1)pdm09 viruses developed severe disease that required euthanasia. When the time between viral infection and bacterial challengewas extended, A/H1N1pdm09-infected animals remained susceptible to SBI- for up to 10 days after the viral infection. For A(H3N2)- but not A(H1N1)pdm09-infected ferrets, susceptibility to SBI-associated disease could be extended out to 16 days postviral infection. While caution should be taken when extrapolating animal models to human infections, the differences between A(H3N2) and A(H1N1)pdm09 strains in duration of susceptibility to SBI observed in the ferret model, may provide some insight regarding the higher rates of SBI-associated disease associated with some strains of A(H3N2) viruses in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Evaluating the fitness of PA/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model.
- Author
-
Lee, Leo YY, Zhou, Jie, Koszalka, Paulina, Frise, Rebecca, Farrukee, Rubaiyea, Baba, Keiko, Miah, Shahjahan, Shishido, Takao, Galiano, Monica, Hashimoto, Takashi, Omoto, Shinya, Uehara, Takeki, Mifsud, Edin J., Collinson, Neil, Kuhlbusch, Klaus, Clinch, Barry, Wildum, Steffen, Barclay, Wendy S., and Hurt, Aeron C.
- Subjects
INFLUENZA viruses ,INFLUENZA A virus ,RECOMBINANT viruses ,FERRET ,ANTIVIRAL agents ,INFLUENZA ,DIVERTICULITIS - Abstract
Baloxavir is approved in several countries for the treatment of uncomplicated influenza in otherwise-healthy and high-risk patients. Treatment-emergent viruses with reduced susceptibility to baloxavir have been detected in clinical trials, but the likelihood of widespread occurrence depends on replication capacity and onward transmission. We evaluated the fitness of A/H3N2 and A/H1N1pdm09 viruses with the polymerase acidic (PA) I38T-variant conferring reduced susceptibility to baloxavir relative to wild-type (WT) viruses, using a competitive mixture ferret model, recombinant viruses and patient-derived virus isolates. The A/H3N2 PA/I38T virus showed a reduction in within-host fitness but comparable between-host fitness to the WT virus, while the A/H1N1pdm09 PA/I38T virus had broadly similar within-host fitness but substantially lower between-host fitness. Although PA/I38T viruses replicate and transmit between ferrets, our data suggest that viruses with this amino acid substitution have lower fitness relative to WT and this relative fitness cost was greater in A/H1N1pdm09 viruses than in A/H3N2 viruses. Author summary: Influenza viruses are associated with considerable disease burden and circulate annually causing seasonal epidemics. Antiviral drugs can be used to treat influenza infections and help reduce the disease burden. Occasionally, treatment can lead to the emergence of viruses with reduced antiviral susceptibility. Normally such viruses have reduced 'fitness', meaning they do not tend to spread or transmit widely, however on rare occasions, oseltamivir-resistant variants have become widespread in the community, thereby reducing the utility of the drug for treatment. Baloxavir is an antiviral recently licensed in many parts of the world for the treatment of influenza. Viruses with reduced susceptibility to baloxavir have been observed in clinical trials, but the frequency of such variants in the community has remained low (<0.1% globally since 2017–2018). We evaluated the fitness of viruses in ferrets and found that although A/H1N1 and A/H3N2 viruses with reduced baloxavir susceptibility were able to replicate and transmit among ferrets, they had a moderate reduction in fitness compared to normal 'wild-type' viruses, suggesting a reduced likelihood of spread. Surveillance to monitor for the frequency of viruses with reduced baloxavir susceptibility remains important. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. A rapid pyrosequencing assay for the molecular detection of influenza viruses with reduced baloxavir susceptibility due to PA/I38X amino acid substitutions.
- Author
-
Koszalka, Paulina, Farrukee, Rubaiyea, Mifsud, Edin, Vijaykrishna, Dhanasekaran, and Hurt, Aeron C.
- Subjects
INFLUENZA viruses ,INFLUENZA B virus ,AMINO acids ,AMINO acid residues - Abstract
Baloxavir marboxil is a novel endonuclease inhibitor licensed for treatment of otherwise healthy or high‐risk individuals infected with influenza. Viruses with reduced baloxavir susceptibility due to amino acid substitutions at residue 38 of the PA have been detected in some individuals following treatment. Here, we describe a genotypic pyrosequencing method that can be used to rapidly screen circulating influenza A and B viruses for substitutions in the PA/I38 codon and to quantify mixed viral populations. This method is suitable for surveillance of baloxavir susceptibility and to analyse samples from hospitalised patients undergoing baloxavir treatment to aid in clinical decision making. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Utilising animal models to evaluate oseltamivir efficacy against influenza A and B viruses with reduced in vitro susceptibility.
- Author
-
Farrukee, Rubaiyea, Tai, Celeste Ming-Kay, Oh, Ding Yuan, Anderson, Danielle E., Gunalan, Vithiagaran, Hibberd, Martin, Lau, Gary Yuk-Fai, Barr, Ian G., Messling, Veronika von, Maurer-Stroh, Sebastian, and Hurt, Aeron C.
- Subjects
INFLUENZA B virus ,INFLUENZA A virus, H1N1 subtype ,INFLUENZA viruses ,ANIMAL models in research ,VIRAL shedding ,SYMPTOMS - Abstract
The neuraminidase (NA) inhibitor (NAI) oseltamivir (OST) is the most widely used influenza antiviral drug. Several NA amino acid substitutions are reported to reduce viral susceptibility to OST in in vitro assays. However, whether there is a correlation between the level of reduction in susceptibility in vitro and the efficacy of OST against these viruses in vivo is not well understood. In this study, a ferret model was utilised to evaluate OST efficacy against circulating influenza A and B viruses with a range of in vitro generated 50% inhibitory concentrations (IC
50 ) values for OST. OST efficacy against an A(H1N1)pdm09 and an A(H1N1)pdm09 virus with the H275Y substitution in neuraminidase was also tested in the macaque model. The results from this study showed that OST had a significant impact on virological parameters compared to placebo treatment of ferrets infected with wild-type influenza A viruses with normal IC50 values (~1 nM). However, this efficacy was lower against wild-type influenza B and other viruses with higher IC50 values. Differing pathogenicity of the viruses made evaluation of clinical parameters difficult, although some effect of OST in reducing clinical signs was observed with influenza A(H1N1) and A(H1N1)pdm09 (H275Y) viruses. Viral titres in macaques were too low to draw conclusive results. Analysis of the ferret data revealed a correlation between IC50 and OST efficacy in reducing viral shedding but highlighted that the current WHO guidelines/criteria for defining normal, reduced or highly reduced inhibition in influenza B viruses based on in vitro data are not well aligned with the low in vivo OST efficacy observed for both wild-type influenza B viruses and those with reduced OST susceptibility. Author summary: Oseltamivir (Tamiflu) is an antiviral widely used for the treatment of infection due to influenza viruses and is especially useful for the treatment of severely ill high-risk patients. Antiviral resistance to oseltamivir is of concern as it can undermine the utility of the drug. Influenza viruses can become less susceptible to oseltamivir due to amino acid substitutions that arise in the viral surface protein, neuraminidase (NA). During influenza surveillance, to monitor for resistance, laboratory experiments are carried out to measure viral susceptibility to oseltamivir, whereby the quantity of drug needed to inhibit NA enzyme action is measured. However, how well these laboratory measurements predict resistance of viruses to oseltamivir in a clinical setting is not well understood. In this study, we developed an animal model to evaluate this relationship between laboratory data and clinical efficacy in more detail and demonstrated that in vivo efficacy of oseltamivir is lower against viruses that show reduced inhibition by oseltamivir in laboratory testing. A key finding from our analysis was that oseltamivir had reduced efficacy in reducing viral shedding against wild-type influenza B viruses compared to wild-type influenza A viruses, which has implications on how data from influenza B viruses with reduced susceptibility are currently being interpreted. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
7. Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission.
- Author
-
Lee, Leo Yi Yang, Zhou, Jie, Frise, Rebecca, Goldhill, Daniel H., Koszalka, Paulina, Mifsud, Edin J., Baba, Kaoru, Noda, Takahiro, Ando, Yoshinori, Sato, Kenji, Yuki, Aoe-Ishikawa, Shishido, Takao, Uehara, Takeki, Wildum, Steffen, Zwanziger, Elke, Collinson, Neil, Kuhlbusch, Klaus, Clinch, Barry, Hurt, Aeron C., and Barclay, Wendy S.
- Subjects
PANDEMICS ,FERRET ,INFLUENZA ,SEASONAL influenza ,INFLUENZA viruses ,VIRAL transmission - Abstract
Influenza viruses cause seasonal outbreaks and pose a continuous pandemic threat. Although vaccines are available for influenza control, their efficacy varies each season and a vaccine for a novel pandemic virus manufactured using current technology will not be available fast enough to mitigate the effect of the first pandemic wave. Antivirals can be effective against many different influenza viruses but have not thus far been used extensively for outbreak control. Baloxavir, a recently licensed antiviral drug that targets the influenza virus endonuclease, has been shown to reduce virus shedding more effectively than oseltamivir, a widely used neuraminidase inhibitor drug. Thus it is possible that treatment with baloxavir might also interrupt onward virus transmission. To test this, we utilized the ferret model, which is the most commonly used animal model to study influenza virus transmission. We established a subcutaneous baloxavir administration method in ferrets which achieved similar pharmacokinetics to the approved human oral dose. Transmission studies were then conducted in two different locations with different experimental setups to compare the onward transmission of A(H1N1)pdm09 virus from infected ferrets treated with baloxavir, oseltamivir or placebo to naïve sentinel ferrets exposed either indirectly in adjacent cages or directly by co-housing. We found that baloxavir treatment reduced infectious viral shedding in the upper respiratory tract of ferrets compared to placebo, and reduced the frequency of transmission amongst sentinels in both experimental setups, even when treatment was delayed until 2 days post-infection. In contrast, oseltamivir treatment did not substantially affect viral shedding or transmission compared to placebo. We did not detect the emergence of baloxavir-resistant variants in treated animals or in untreated sentinels. Our results support the concept that antivirals which decrease viral shedding could also reduce influenza transmission in the community. Author summary: During seasonal influenza outbreaks and global pandemics, influenza can cause significant morbidity and mortality and spread rapidly. Influenza viruses constantly change, and the effectiveness of vaccination can be low if the match between the vaccine and circulating viruses is poor. However, antiviral drugs target conserved parts of the virus and therefore typically remain effective against new seasonal or pandemic strains of influenza. The new antiviral baloxavir is more effective than existing drugs, such as oseltamivir, in reducing the amount of virus particles produced by infected people, suggesting it might reduce the onward spread of influenza viruses to others. To test this, we developed an effective way to deliver baloxavir to ferrets, the best available animal model of influenza virus transmission. We then treated influenza-infected ferrets with baloxavir to determine if they were less likely to pass their virus onto healthy ferrets housed in the same cage, or in the adjacent cage. In both cases, we found that compared to oseltamivir or placebo treatment, infected ferrets treated with baloxavir produced fewer virus particles and were less likely to transmit virus to healthy ferrets. Our results suggest baloxavir can contribute to the early control of influenza outbreaks by limiting community-based viral spread. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza.
- Author
-
Uehara, Takeki, Hayden, Frederick G, Kawaguchi, Keiko, Omoto, Shinya, Hurt, Aeron C, Jong, Menno D De, Hirotsu, Nobuo, Sugaya, Norio, Lee, Nelson, Baba, Keiko, Shishido, Takao, Tsuchiya, Kenji, Portsmouth, Simon, Kida, Hiroshi, and De Jong, Menno D
- Subjects
INFLUENZA viruses ,AMINO acids ,INFLUENZA ,SULFUR compounds ,PYRIDINE ,RESEARCH ,HETEROCYCLIC compounds ,VIRAL load ,RESEARCH methodology ,ANTIVIRAL agents ,EVALUATION research ,MEDICAL cooperation ,TREATMENT effectiveness ,COMPARATIVE studies ,BLIND experiment ,DRUG resistance in microorganisms ,INFLUENZA A virus, H3N2 subtype ,OSELTAMIVIR ,PHARMACODYNAMICS - Abstract
Background: Single-dose baloxavir rapidly reduces influenza virus titers and symptoms in patients with uncomplicated influenza, but viruses with reduced in vitro susceptibility due to amino acid substitutions at position 38 of polymerase acidic protein (PA/I38X) sometimes emerge.Methods: We evaluated the kinetics, risk factors, and effects on clinical and virologic outcomes of emergence of PA/I38X-substituted viruses.Results: Viruses containing PA/I38X substitutions were identified 3-9 days after baloxavir treatment in 9.7% (36/370) of patients, of whom 85.3% had transient virus titer rises. Median time to sustained cessation of infectious virus detection was 192, 48, and 96 hours in the baloxavir recipients with PA/I38X-substituted viruses, without PA/I38X-substituted viruses, and placebo recipients, respectively. The corresponding median times to alleviation of symptoms were 63.1, 51.0, and 80.2 hours, respectively. After day 5, symptom increases occurred in 11.5%, 8.0%, and 13.0%, respectively, and in 8.9% of oseltamivir recipients. Variant virus emergence was associated with lower baseline neutralizing antibody titers.Conclusions: The emergence of viruses with PA/I38X substitutions following baloxavir treatment was associated with transient rises in infectious virus titers, prolongation of virus detectability, initial delay in symptom alleviation, and uncommonly with symptom rebound. The potential transmissibility of PA/I38X-substituted viruses requires careful study.Clinical Trial Registration: NCT02954354. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
9. Genetic variations on 31 and 450 residues of influenza A nucleoprotein affect viral replication and translation.
- Author
-
Hung, Su-Jhen, Hsu, Yin-Mei, Huang, Sheng-Wen, Tsai, Huey-Pin, Lee, Leo Yi Yang, Hurt, Aeron C., Barr, Ian G., Shih, Shin-Ru, and Wang, Jen-Ren
- Subjects
VIRAL replication ,INFLUENZA A virus, H3N2 subtype ,INFLUENZA ,RNA synthesis ,INFLUENZA viruses ,VIRAL shedding ,VIRAL proteins - Abstract
Background: Influenza A viruses cause epidemics/severe pandemics that pose a great global health threat. Among eight viral RNA segments, the multiple functions of nucleoprotein (NP) play important roles in viral replication and transcription. Methods: To understand how NP contributes to the virus evolution, we analyzed the NP gene of H3N2 viruses in Taiwan and 14,220 NP sequences collected from Influenza Research Database. The identified genetic variations were further analyzed by mini-genome assay, virus growth assay, viral RNA and protein expression as well as ferret model to analyze their impacts on viral replication properties. Results: The NP genetic analysis by Taiwan and global sequences showed similar evolution pattern that the NP backbones changed through time accompanied with specific residue substitutions from 1999 to 2018. Other than the conserved residues, fifteen sporadic substitutions were observed in which the 31R, 377G and 450S showed higher frequency. We found 31R and 450S decreased polymerase activity while the dominant residues (31 K and 450G) had higher activity. The 31 K and 450G showed better viral translation and replication in vitro and in vivo. Conclusions: These findings indicated variations identified in evolution have roles in modulating viral replication in vitro and in vivo. This study demonstrates that the interaction between variations of NP during virus evolution deserves future attention. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Circulation and characterization of seasonal influenza viruses in Cambodia, 2012‐2015.
- Author
-
Horwood, Paul F., Karlsson, Erik A., Horm, Srey Viseth, Ly, Sovann, Heng, Seng, Chin, Savuth, Darapheak, Chau, Saunders, David, Chanthap, Lon, Rith, Sareth, Y, Phalla, Chea, Kim Lay, Sar, Borann, Parry, Amy, Ieng, Vanra, Tsuyouka, Reiko, Deng, Yi‐Mo, Hurt, Aeron C., Barr, Ian G., and Komadina, Naomi
- Subjects
SEASONAL influenza ,INFLUENZA viruses ,INFLUENZA A virus ,INFLUENZA A virus, H1N1 subtype ,MEDICAL sciences ,INFLUENZA B virus ,INFLUENZA ,ANTIVIRAL agents - Abstract
Background: Influenza virus circulation is monitored through the Cambodian influenza‐like illness (ILI) sentinel surveillance system and isolates are characterized by the National Influenza Centre (NIC). Seasonal influenza circulation has previously been characterized by year‐round activity and a peak during the rainy season (June‐November). Objectives: We documented the circulation of seasonal influenza in Cambodia for 2012‐2015 and investigated genetic, antigenic, and antiviral resistance characteristics of influenza isolates. Patients/Methods: Respiratory samples were collected from patients presenting with influenza‐like illness (ILI) at 11 hospitals throughout Cambodia. First‐line screening was conducted by the National Institute of Public Health and the Armed Forces Research Institute of Medical Sciences. Confirmation of testing and genetic, antigenic and antiviral resistance characterization was conducted by Institute Pasteur in Cambodia, the NIC. Additional virus characterization was conducted by the WHO Collaborating Centre for Reference and Research on Influenza (Melbourne, Australia). Results: Between 2012 and 2015, 1,238 influenza‐positive samples were submitted to the NIC. Influenza A(H3N2) (55.3%) was the dominant subtype, followed by influenza B (30.9%; predominantly B/Yamagata‐lineage) and A(H1N1)pdm09 (13.9%). Circulation of influenza viruses began earlier in 2014 and 2015 than previously described, coincident with the emergence of A(H3N2) clades 3C.2a and 3C.3a, respectively. There was high diversity in the antigenicity of A(H3N2) viruses, and to a smaller extent influenza B viruses, during this period, with some mismatches with the northern and southern hemisphere vaccine formulations. All isolates tested were susceptible to the influenza antiviral drugs oseltamivir and zanamivir. Conclusions: Seasonal and year‐round co‐circulation of multiple influenza types/subtypes were detected in Cambodia during 2012‐2015. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. Influenza viruses with B/Yamagata- and B/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility.
- Author
-
Farrukee, Rubaiyea, Leang, Sook-Kwan, Butler, Jeff, Lee, Raphael T. C., Maurer-Stroh, Sebastian, Tilmanis, Danielle, Sullivan, Sheena, Mosse, Jennifer, Barr, Ian G., and Hurt, Aeron C.
- Subjects
NEURAMINIDASE ,INFLUENZA viruses ,OSELTAMIVIR ,RELENZA (Drug) ,DRUG resistance in bacteria ,INFLUENZA B virus ,DISEASE susceptibility - Abstract
Objectives: The burden of disease due to influenza B is often underestimated. Clinical studies have shown that oseltamivir, a widely used neuraminidase inhibitor (NAI) antiviral drug, may have reduced effectiveness against influenza B viruses. Therefore, it is important to study the effect of neuraminidasemutations in influenza B viruses that may further reduce NAI susceptibility, and to determine whether these mutations have the same effect in the two lineages of influenza B viruses that are currently circulating (B/Yamagata-like and B/Victoria-like). Methods:We characterized the effect of 16 amino acid substitutions across five framework residues and four monomeric interface residues on the susceptibility to four different NAIs (oseltamivir, zanamivir, peramivir and laninamivir). Results: Framework residue mutations E117A and E117G conferred highly reduced inhibition to three of the four NAIs, but substantially reduced neuraminidase activity, whereas other framework mutations retained a greater level of NA activity. Mutations E105K, P139S and G140R of themonomeric interfacewere also found to cause highly reduced inhibition, but, interestingly, their effect was substantially greater in a B/Victoria-like neuraminidase than in a B/Yamagata-like neuraminidase, with some susceptibility values being up to 1000-fold different between lineages. Conclusions: The frequency and the effect of key neuraminidase mutations on neuraminidase activity and NAI susceptibility can differ substantially between the two influenza B lineages. Therefore, future surveillance, analysis and interpretation of influenza B virus NAI susceptibility should consider the B lineage of the neuraminidase in the same manner as already occurs for different influenza A neuraminidase subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Oseltamivir Prophylaxis Reduces Inflammation and Facilitates Establishment of Cross-Strain Protective T Cell Memory to Influenza Viruses.
- Author
-
Bird, Nicola L., Olson, Matthew R., Hurt, Aeron C., Oshansky, Christine M., Oh, Ding Yuan, Reading, Patrick C., Chua, Brendon Y., Sun, Yilun, Tang, Li, Handel, Andreas, Jackson, David C., Turner, Stephen J., Thomas, Paul G., and Kedzierska, Katherine
- Subjects
INFLAMMATION ,OSELTAMIVIR ,DENTAL prophylaxis ,T cells ,INFLUENZA viruses ,CD8 antigen - Abstract
CD8
+ T cells directed against conserved viral regions elicit broad immunity against distinct influenza viruses, promote rapid virus elimination and enhanced host recovery. The influenza neuraminidase inhibitor, oseltamivir, is prescribed for therapy and prophylaxis, although it remains unclear how the drug impacts disease severity and establishment of effector and memory CD8+ T cell immunity. We dissected the effects of oseltamivir on viral replication, inflammation, acute CD8+ T cell responses and the establishment of immunological CD8+ T cell memory. In mice, ferrets and humans, the effect of osteltamivir on viral titre was relatively modest. However, prophylactic oseltamivir treatment in mice markedly reduced morbidity, innate responses, inflammation and, ultimately, the magnitude of effector CD8+ T cell responses. Importantly, functional memory CD8+ T cells established during the drug-reduced effector phase were capable of mounting robust recall responses. Moreover, influenza-specific memory CD4+ T cells could be also recalled after the secondary challenge, while the antibody levels were unaffected. This provides evidence that long-term memory T cells can be generated during an oseltamivir-interrupted infection. The anti-inflammatory effect of oseltamivir was verified in H1N1-infected patients. Thus, in the case of an unpredicted influenza pandemic, while prophylactic oseltamivir treatment can reduce disease severity, the capacity to generate memory CD8+ T cells specific for the newly emerged virus is uncompromised. This could prove especially important for any new influenza pandemic which often occurs in separate waves. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
13. Mutations I117V and I117M and Oseltamivir Sensitivity of Pandemic (H1N1) 2009 Viruses.
- Author
-
Hurt, Aeron C., Leang, Sook Kwan, Speers, David J., Barr, Ian G., and Maurer-Stroh, Sebastian
- Subjects
- *
INFLUENZA research , *INFLUENZA viruses , *OSELTAMIVIR , *GENETIC mutation , *PANDEMICS , *EMERGING infectious diseases - Abstract
Analysis of mutations I117V and I117M in the neuraminidase of influenza A pandemic (H1N1) 2009 viruses showed that I117V confers a mild reduction in oseltamivir sensitivity and has a synergistic effect of further increasing resistance when combined with H275Y. Contrary to recent reports, the I117M mutation does not alter oseltamivir sensitivity. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. Continued dominance of pandemic A(H1N1) 2009 influenza in Victoria, Australia in 2010.
- Author
-
Grant, Kristina A., Franklin, Lucinda J., Kaczmarek, Marlena., Hurt, Aeron C., Kostecki, Renata, Kelly, Heath A., and Fielding, James E.
- Subjects
H1N1 influenza ,VACCINATION ,PREVENTION of communicable diseases ,INFLUENZA viruses ,OSELTAMIVIR ,NEURAMINIDASE - Abstract
The 2010 Victorian influenza season was characterized by normal seasonal influenza activity and the dominance of the pandemic A(H1N1) 2009 strain. General Practice Sentinel Surveillance rates peaked at 9.4 ILI cases per 1000 consultations in week 36 for metropolitan practices, and at 10.5 ILI cases per 1000 in the following week for rural practices. Of the 678 ILI cases, 23% were vaccinated, a significantly higher percentage than in previous years. A significantly higher percentage of ILI patients were swabbed in 2010 compared to 2003-2008, but similar to 2009, with a similar percentage being positive for influenza as in previous years. Vaccination rates increased with patient age. Melbourne Medical Deputising Service rates peaked in week 35 at 19.1 ILI cases per 1000 consultations. Of the 1914 cases of influenza notified to the Department of Health, Victoria, 1812 (95%) were influenza A infections - 1001 (55%) pandemic A(H1N1) 2009, 4 (<1%) A(H3N2) and 807 (45%) not subtyped; 88 (5%) were influenza B; and 14 (<1%) were influenza A and B co-infections. The World Health Organization Collaborating Centre for Reference and Research on Influenza tested 403 isolates of which 261 were positive for influenza, 250 of which were influenza A and 11 were influenza B. Ninety-two per cent of the influenza A viruses were pandemic A(H1N1) 2009, and following antigenic analysis all of these were found to be similar to the current vaccine strain. Three viruses (0.9%) were found to be oseltamivir resistant due to an H275Y mutation in the neuraminidase gene. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. Surveillance and Analysis of Avian Influenza Viruses, Australia.
- Author
-
Hansbro, Philip M., Warner, Simone, Tracey, John P., Arzey, K. Edla, Selleck, Paul, O'Riley, Kim, Beckett, Emma L., Bunn, Chris, Kirkland, Peter D., Vijaykrishna, Dhanasekaran, Olsen, Bjorn, and Hurt, Aeron C.
- Subjects
AVIAN influenza ,INFLUENZA viruses ,VETERINARY virology ,PANDEMICS ,VIRUS diseases in poultry - Abstract
We investigated carriage of avian influenza viruses by wild birds in Australia, 2005-2008, to assess the risks to poultry industries and human health. We collected 21,858 (7,357 cloacal, 14,501 fecal) samples and detected 300 viruses, representing a detection rate of =1.4%. Rates were highest in autumn (March-May) and differed substantially between bird types, areas, and years. We typed 107 avian influenza viruses and identified 19 H5, 8 H7, and 16 H9 (40% of typed viruses). All were of low pathogenicity. These viruses formed clearly different phylogenetic clades to lineages from Eurasia or North America, suggesting the potential existence of Australian lineages. H7 viruses were similar to highly pathogenic H7 strains that caused outbreaks in poultry in Australia. Several periods of increased detection rates (numbers or subtypes of viruses) were identified. This study demonstrates the need for ongoing surveillance to detect emerging pathogenic strains and facilitate prevention of outbreaks. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
16. Assessing the Viral Fitness of Oseltamivir-Resistant Influenza Viruses in Ferrets, Using a Competitive-Mixtures Model.
- Author
-
Hurt, Aeron C., Nor'e, Siti Sarah, McCaw, James M., Fryer, Helen R., Mosse, Jennifer, McLean, Angela R., and Barr, Ian G.
- Subjects
- *
RESPIRATORY infections , *INFLUENZA viruses , *VIRUS diseases , *MICROORGANISMS , *INFLUENZA - Abstract
To determine the relative fitness of oseltamivir-resistant strains compared to susceptible wild-type viruses, we combined mathematical modeling and statistical techniques with a novel in vivo "competitive-mixtures" experimental model. Ferrets were coinfected with either pure populations (100% susceptible wild-type or 100% oseltamivir-resistant mutant virus) or mixed populations of wild-type and oseltamivir-resistant influenza viruses (80%:20%, 50%:50%, and 20%:80%) at equivalent infectivity titers, and the changes in the relative proportions of those two viruses were monitored over the course of the infection during within-host and over host-to-host transmission events in a ferret contact model. Coinfection of ferrets with mixtures of an oseltamivir- resistant R292K mutant A(H3N2) virus and a R292 oseltamivir-susceptible wild-type virus demonstrated that the R292K mutant virus was rapidly outgrown by the R292 wild-type virus in artificially infected donor ferrets and did not transmit to any of the recipient ferrets. The competitive-mixtures model was also used to investigate the fitness of the seasonal A(H1N1) oseltamivir-resistant H274Y mutant and showed that within infected ferrets the H274Y mutant virus was marginally outgrown by the wild-type strain but demonstrated equivalent transmissibility between ferrets. This novel in vivo experimental method and accompanying mathematical analysis provide greater insight into the relative fitness, both within the host and between hosts, of two different influenza virus strains compared to more traditional methods that infect ferrets with only pure populations of viruses. Our statistical inferences are essential for the development of the next generation of mathematical models of the emergence and spread of oseltamivir-resistant influenza in human populations. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
17. Assessing the development of oseltamivir and zanamivir resistance in A(H5N1) influenza viruses using a ferret model
- Author
-
Hurt, Aeron C., Lowther, Sue, Middleton, Deborah, and Barr, Ian G.
- Subjects
- *
INFLUENZA viruses , *FERRETS as laboratory animals , *ANTIVIRAL agents , *NEURAMINIDASE , *DRUG dosage , *THERAPEUTICS , *GLUTAMINE , *LEUCINE , *GENETIC mutation , *INFLUENZA A virus, H5N1 subtype - Abstract
Abstract: Using an in vivo ferret model, we investigated the development of resistance to oseltamivir and zanamivir for two different influenza A(H5N1) viruses (A/Vietnam/1203/2004, haemagglutinin phylogenetic clade 1, and A/Chicken/Laos/26/2006, haemagglutinin phylogenetic clade 2.3) by treating the animals with doses equivalent either to the recommended human treatment dose or a range of sub-optimal drug doses. No resistance was observed in oseltamivir-treated ferrets, but analysis of nasal washes from zanamivir-treated ferrets infected with influenza A/Vietnam/1203/2004 revealed one viral isolate (from a ferret receiving the highest dose of zanamivir, 1.0mg/kg twice daily) with a zanamivir IC50 that was 350-fold higher than the other isolates tested. The same virus also demonstrated a 26-fold increase in oseltamivir IC50. The isolate with reduced susceptibility was taken from a ferret 8 days post-infection that was being treated with the recommended human zanamivir dose. Sequence analysis of the resistant virus revealed a glutamine (Q) to leucine (L) mutation at residue 136 of the neuraminidase. This is the first report of this mutation being associated with neuraminidase inhibitor susceptibility and one of the few reported mutations that confer zanamivir resistance, and as such should be closely monitored in influenza A(H5N1) and other N1 viruses in the future. Further animal studies and human clinical trials are necessary to optimize neuraminidase inhibitor dosing strategies for the treatment of influenza A(H5N1) infections. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
18. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa
- Author
-
Hurt, Aeron C., Ernest, Joanne, Deng, Yi-Mo, Iannello, Pina, Besselaar, Terry G., Birch, Chris, Buchy, Philippe, Chittaganpitch, Malinee, Chiu, Shu-Chun, Dwyer, Dominic, Guigon, Aurélie, Harrower, Bruce, Kei, Ip Peng, Kok, Tuckweng, Lin, Cui, McPhie, Ken, Mohd, Apandi, Olveda, Remigio, Panayotou, Tony, and Rawlinson, William
- Subjects
- *
INFLUENZA viruses - Abstract
Abstract: The neuraminidase inhibitors (NAIs) are an effective class of antiviral drugs for the treatment of influenza A and B infections. Until recently, only a low prevalence of NAI resistance (<1%) had been detected in circulating viruses. However, surveillance in Europe in late 2007 revealed significant numbers of A(H1N1) influenza strains with a H274Y neuraminidase mutation that were highly resistant to the NAI oseltamivir. We examined 264 A(H1N1) viruses collected in 2008 from South Africa, Oceania and SE Asia for their susceptibility to NAIs oseltamivir, zanamivir and peramivir in a fluorescence-based neuraminidase inhibition assay. Viruses with reduced oseltamivir susceptibility were further analysed by pyrosequencing assay. The frequency of the oseltamivir-resistant H274Y mutant increased significantly after May 2008, resulting in an overall proportion of 64% (168/264) resistance among A(H1N1) strains, although this subtype represented only 11.6% of all isolates received during 2008. H274Y mutant viruses demonstrated on average a 1466-fold reduction in oseltamivir susceptibility and 527-fold reduction in peramivir sensitivity compared to wild-type A(H1N1) viruses. The mutation had no impact on zanamivir susceptibility. Ongoing surveillance is essential to monitor how these strains may spread or persist in the future and to evaluate the effectiveness of treatments against them. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
19. Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.
- Author
-
Guillonneau, Carole, Mintern, Justine D., Hubert, Francois-Xavier, Hurt, Aeron C., Besra, Gurdyal S., Porcelli, Steven, Barr, Ian G., Doherty, Peter C., Godfrey, Dale I., and Turner, Stephen J.
- Subjects
INFLUENZA viruses ,INFLUENZA ,VACCINATION ,IMMUNOGENETICS ,WILDLIFE refuges ,VACCINES - Abstract
Current influenza A virus vaccines do not generate significant immunity against serologically distinct influenza A virus subtypes and would thus be ineffective in the face of a pandemic caused by a novel variant emerging from, say, a wildlife reservoir. One possible solution would be to modify these vaccines so that they prime cross-reactive CD8~ cytotoxic T lymphocytes (CTL) cell- mediated immunity directed at conserved viral epitopes. A further strategy is to use novel adjuvants, such as the immunomodulatory glycolipid α-galactosylceramide (α-GalCer). We show here that giving α-GalCer with an inactivated influenza A virus has the paradoxical effect of diminishing acute CIL immunity via natural killer T (NKT) cell-dependent expression of indoleamine 2,3-dioxygenase (IDO), an important mediator of immune suppression, while at the same time promoting the survival of long-lived memory CTL populations capable of boosting protection against heterologous influenza A virus challenge. This enhancement of memory was likely due to the α-GalCer-induced upregulation of prosurvival genes, such as bcl-2, and points to the potential of α-GalCer as an adjuvant,for promoting optimal, vaccine-induced CD8
+ T cell memory. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
20. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors.
- Author
-
Hurt, Aeron C., Hui-Ting Ho, and Barr, Ian
- Subjects
INFLUENZA ,THERAPEUTICS ,ADAMANTANE ,NEURAMINIDASE ,DRUG resistance ,INFLUENZA viruses - Abstract
Development of effective drugs for the treatment or prevention of epidemic and pandemic influenza is important in order to reduce its impact. Adamantanes and neuraminidase inhibitors are two classes of anti-influenza drugs available for influenza therapy currently. However, emergence of resistance to these drugs has been detected, which raises concerns regarding their widespread use. In this review, resistance to the adamantanes and neuraminidase inhibitors will be discussed in relation to both epidemic and pandemic influenza viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
21. Burden of influenza B virus infection and considerations for clinical management.
- Author
-
Zaraket, Hassan, Hurt, Aeron C., Clinch, Barry, Barr, Ian, and Lee, Nelson
- Subjects
- *
INFLUENZA B virus , *VIRUS diseases , *INFLUENZA , *PANDEMICS , *CHILD mortality , *CHILD patients , *RANDOMIZED controlled trials , *INFLUENZA viruses - Abstract
Influenza B viruses cause significant morbidity and mortality, particularly in children, but the awareness of their impact is often less than influenza A viruses partly due to their lack of pandemic potential. Here, we summarise the biology, epidemiology and disease burden of influenza B, and review existing data on available antivirals for its management. There has long been uncertainty surrounding the clinical efficacy of neuraminidase inhibitors (NAIs) for influenza B treatment. In this article, we bring together the existing data on NAIs and discuss these alongside recent large randomised controlled trial data for the new polymerase inhibitor baloxavir in high-risk influenza B patients. Finally, we offer considerations for the clinical management of influenza B, with a focus on children and high-risk patients where disease burden is highest. • Influenza B viruses are associated with significant morbidity and mortality, especially in children. • Available evidence suggests neuraminidase inhibitors are less effective at treating influenza B versus A infections. • Phase 3 trial data show the polymerase inhibitor baloxavir is effective in influenza B patients and resistance is rare. • Single oral dose baloxavir offers a more effective and convenient treatment of influenza B than neuraminidase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. The Ongoing Battle Against Influenza: Drug-resistant influenza viruses: why fitness matters.
- Author
-
Kelso, Anne and Hurt, Aeron C
- Subjects
- *
OSELTAMIVIR , *INFLUENZA viruses , *INFLUENZA prevention , *PANDEMICS , *HOSPITAL patients , *VIRUS disease transmission , *PREVENTION - Abstract
The article informs about the oseltamivir, a drug used for the treatment of infection caused by influenza viruses. It informs that the influenza neuraminidase inhibitors oseltamivir and zanamivir have been available for the treatment of influenza and countries have acquired stockpiles to be used in a pandemic. It mentions that proper care should be taken for minimizing the risk of virus transmission from the hospitalized patients who are undergoing the oseltamivir treatment.
- Published
- 2012
- Full Text
- View/download PDF
23. Induction of Interferon-Stimulated Genes Correlates with Reduced Growth of Influenza A Virus in Lungs after RIG-I Agonist Treatment of Ferrets.
- Author
-
Schwab, Lara S. U., Londrigan, Sarah L., Brooks, Andrew G., Hurt, Aeron C., Sahu, Anshupa, Yi-Mo Deng, Moselen, Jean, Coch, Christoph, Zillinger, Thomas, Hartmann, Gunther, and Readinga, Patrick C.
- Subjects
- *
VIRAL shedding , *INFLUENZA A virus , *RNA virus infections , *MONONUCLEAR leukocytes , *INFLUENZA viruses , *FERRET , *VIRAL transmission - Abstract
Intracellular RIG-I receptors represent key innate sensors of RNA virus infection, and RIG-I activation results in the induction of hundreds of host effector genes, including interferon-stimulated genes (ISGs). Synthetic RNA agonists targeting RIG-I have shown promise as antivirals against a broad spectrum of viruses, including influenza A virus (IAV), in both in vitro and mouse models of infection. Herein, we demonstrate that treatment of a ferret airway epithelial (FRL) cell line with a RIG-I agonist rapidly and potently induced expression of a broad range of ISGs and resulted in potent inhibition of growth of different IAV strains. In ferrets, a single intravenous injection of RIG-I agonist was associated with upregulated ISG expression in peripheral blood mononuclear cells and lung tissue, but not in nasal tissues. In a ferret model of viral contact transmission, a single treatment of recipient animals 24 h prior to cohousing with IAV-infected donors did not reduce virus transmission and shedding but did result in reduced lung virus titers 6 days after treatment. A single treatment of the IAV-infected donor animals also resulted in reduced virus titers in the lungs 2 days later. Thus, a single intravenous treatment with RIG-I agonist prior to infection or to ferrets with an established IAV infection can reduce virus growth in the lungs. These findings support further development of RIG-I agonists as effective antiviral treatments to limit the impact of IAV infections, particularly in reducing virus replication in the lower airways. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution.
- Author
-
Farrukee, Rubaiyea, Gunalan, Vithiagaran, Maurer-Stroh, Sebastian, Reading, Patrick C., and Hurt, Aeron C.
- Subjects
- *
INFLUENZA viruses , *NEURAMINIDASE , *VIRAL mutation , *INFLUENZA A virus , *AMINO acids , *FERRET - Abstract
Oseltamivir-resistant influenza viruses arise due to amino acid mutations in key residues of the viral neuraminidase (NA). These changes often come at a fitness cost; however, it is known that permissive mutations in the viral NA can overcome this cost. This result was observed in former seasonal A(H1N1) viruses in 2007 which expressed the H275Y substitution (N1 numbering) with no apparent fitness cost and lead to widespread oseltamivir resistance. Therefore, this study aims to predict permissive mutations that may similarly enable fit H275Y variants to arise in currently circulating A(H1N1)pdm09 viruses. The first approach in this study utilized in silico analyses to predict potentially permissive mutations. The second approach involved the generation of a virus library which encompassed all possible NA mutations while keeping H275Y fixed. Fit variants were then selected by serially passaging the virus library either through ferrets by transmission or passaging once in vitro. The fitness impact of selected substitutions was further evaluated experimentally. The computational approach predicted three candidate permissive NA mutations which, in combination with each other, restored the replicative fitness of an H275Y variant. The second approach identified a stringent bottleneck during transmission between ferrets; however, three further substitutions were identified which may improve transmissibility. A comparison of fit H275Y variants in vitro and in experimentally infected animals showed a statistically significant correlation in the variants that were positively selected. Overall, this study provides valuable tools and insights into potential permissive mutations that may facilitate the emergence of a fit H275Y A(H1N1)pdm09 variant. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Reassortment and Persistence of Influenza A Viruses from Diverse Geographic Origins within Australian Wild Birds: Evidence from a Small, Isolated Population of Ruddy Turnstones.
- Author
-
Hoye, Bethany J., Donato, Celeste M., Lisovski, Simeon, Yi-Mo Deng, Warner, Simone, Hurt, Aeron C., Klaassen, Marcel, and Vijaykrishna, Dhanasekaran
- Subjects
- *
AVIAN influenza , *INFLUENZA viruses , *INFLUENZA A virus , *AVIAN influenza A virus , *INFLUENZA A virus, H1N1 subtype , *CHARADRIIFORMES , *GENES - Abstract
Australian lineages of avian influenza A viruses (AIVs) are thought to be phylogenetically distinct from those circulating in Eurasia and the Americas, suggesting the circulation of endemic viruses seeded by occasional introductions from other regions. However, processes underlying the introduction, evolution and maintenance of AIVs in Australia remain poorly understood. Waders (order Charadriiformes, family Scolopacidae) may play a unique role in the ecology and evolution of AIVs, particularly in Australia, where ducks, geese, and swans (order Anseriformes, family Anatidae) rarely undertake intercontinental migrations. Across a 5-year surveillance period (2011 to 2015), ruddy turnstones (Arenaria interpres) that "overwinter" during the Austral summer in southeastern Australia showed generally low levels of AIV prevalence (0 to 2%). However, in March 2014, we detected AIVs in 32% (95% confidence interval [CI], 25 to 39%) of individuals in a small, low-density, island population 90 km from the Australian mainland. This epizootic comprised three distinct AIV genotypes, each of which represent a unique reassortment of Australian-, recently introduced Eurasian-, and recently introduced American-lineage gene segments. Strikingly, the Australian-lineage gene segments showed high similarity to those of H10N7 viruses isolated in 2010 and 2012 from poultry outbreaks 900 to 1,500 km to the north. Together with the diverse geographic origins of the American and Eurasian gene segments, these findings suggest extensive circulation and reassortment of AIVs within Australian wild birds over vast geographic distances. Our findings indicate that long-term surveillance in waders may yield unique insights into AIV gene flow, especially in geographic regions like Oceania, where Anatidae species do not display regular inter- or intracontinental migration. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Antivirals targeting the polymerase complex of influenza viruses.
- Author
-
Mifsud, Edin J., Hayden, Frederick G., and Hurt, Aeron C.
- Subjects
- *
NEURAMINIDASE , *INFLUENZA viruses , *INFLUENZA B virus , *RNA polymerases , *ANTIVIRAL agents - Abstract
Current influenza antivirals have limitations with regard to their effectiveness and the potential emergence of resistance. Encouragingly, several new compounds which inhibit the polymerase of influenza viruses have recently been shown to have enhanced pre-clinical and clinical effectiveness compared to the neuraminidase inhibitors, the mainstay of influenza antiviral therapy over the last two decades. In this review we focus on four compounds which inhibit polymerase function, baloxavir marboxil, favipiravir, pimodivir and AL-794 and discuss their clinical and virological effectiveness, their propensity to select for resistance and their potential for future combination therapy with the most commonly used neuraminidase inhibitor, oseltamivir. • Antiviral compounds targeting components of the polymerase complex PB1, PB2, and PA, are undergoing clinical investigation. • Baloxavir targets endonuclease activity of the PA polymerase subunit and was recently liscensed in Japan and USA for the treatment of influenza A and B viruses. • Favipiravir, a broad spectrum antiviral compound inhibits viral RNA polymerases and has limited licensure in Japan. • Pimodivir targets PB2 subunit of influenza A viruses preventing binding to 7-methyl GTP cap structures. • AL-794 binds to the endonuclease domain of PA but is no longer being evaluated for clinical use. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
27. Baloxavir marboxil susceptibility of influenza viruses from the Asia-Pacific, 2012–2018.
- Author
-
Koszalka, Paulina, Tilmanis, Danielle, Roe, Merryn, Vijaykrishna, Dhanasekaran, and Hurt, Aeron C.
- Subjects
- *
NEURAMINIDASE , *INFLUENZA A virus, H1N1 subtype , *INFLUENZA viruses - Abstract
Abstract Baloxavir Marboxil (BXM) is an influenza polymerase inhibitor antiviral that binds to the endonuclease region in the PA subunit of influenza A and B viruses. To establish the baseline susceptibility of viruses circulating prior to licensure of BXM and to monitor for susceptibility post-BXM use, a cell culture-based focus reduction assay was developed to determine the susceptibility of 286 circulating seasonal influenza viruses, A(H1N1)pdm09, A(H3N2), B (Yamagata/Victoria) lineage viruses, including neuraminidase inhibitor (NAI) resistant viruses, to Baloxavir Acid (BXA), the active metabolic form of BXM. BXA was effective against all influenza subtypes tested with mean EC 50 values (minimum-maximum) of 0.7 ± 0.5 nM (0.1–2.1 nM), 1.2 ± 0.6 nM (0.1–2.4), 7.2 ± 3.5 nM (0.7–14.8), and 5.8 ± 4.5 nM (1.8–15.5) obtained for A(H1N1)pdm09, A(H3N2), B(Victoria lineage), and B(Yamagata lineage) influenza viruses, respectively. Using reverse genetics, amino acid substitutions known to alter BXA susceptibility were introduced into the PA protein resulting in EC 50 fold change increases that ranged from 2 to 65. Our study demonstrates that currently circulating viruses are susceptible to BXA and that the newly developed focus reduction assay is well suited to susceptibility monitoring in reference laboratories. Highlights • A focus reduction assay was developed to determine baloxavir susceptibility in seasonal influenza viruses. • 286 viruses of all seasonal influenza subtypes and lineages tested were susceptible to baloxavir. • The focus reduction assay was amenable to detecting viruses with reduced susceptibility to baloxavir. • PA N protein substitutions at position 38 derived by reverse genetics resulted in up to a 65 fold reduction in baloxavir EC 50. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
28. Influenza A(H5N1) viruses with A(H9N2) single gene (matrix or PB1) reassortment isolated from Cambodian live bird markets.
- Author
-
Suttie, Annika, Karlsson, Erik A., Deng, Yi-Mo, Horm, Srey Viseth, Yann, Sokhoun, Tok, Songha, Sorn, San, Holl, Davun, Tum, Sothyra, Hurt, Aeron C., Greenhill, Andrew R., Barr, Ian G., Horwood, Paul F., and Dussart, Philippe
- Subjects
- *
AVIAN influenza , *INFLUENZA viruses , *VIRAL genes , *PUBLIC health , *GENES - Abstract
Abstract Live bird market surveillance for avian influenza viruses in Cambodia in 2015 has led to the detection of two 7:1 reassortant influenza A(H5N1) clade 2.3.2.1c viruses. These reassortant strains, designated A/duck/Cambodia/Z564W35M1/2015 and A/chicken/Cambodia/Z850W49M1/2015, both contained a single gene (PB1 and matrix gene, respectively) from concurrently circulating A(H9N2) influenza viruses. All other viral genes from both isolates clustered with A(H5N1) clade 2.3.2.1 viruses. Continued and prolonged co-circulation of influenza A(H5N1) and A(H9N2) viruses in Cambodian live bird markets may present a risk for the emergence of novel influenza reassortant viruses with negative agricultural and/or public health implications. Highlights • Two 7:1A(H5N1) reassortant viruses were isolated from Cambodian live bird markets. • Viruses contained single genes (PB1 and matrix gene) from A(H9N2) influenza viruses. • Emergence of novel avian influenza reassortants presents a public health risk. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
29. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016–2017.
- Author
-
Lackenby, Angie, Besselaar, Terry G., Daniels, Rod S., Fry, Alicia, Gregory, Vicki, Gubareva, Larisa V., Huang, Weijuan, Hurt, Aeron C., Leang, Sook-Kwan, Lee, Raphael T.C., Lo, Janice, Lollis, Lori, Maurer-Stroh, Sebastian, Odagiri, Takato, Pereyaslov, Dmitriy, Takashita, Emi, Wang, Dayan, Zhang, Wenqing, and Meijer, Adam
- Subjects
- *
DISEASE susceptibility , *INFLUENZA viruses , *NEURAMINIDASE , *ANTIVIRAL agents , *CLINICAL trials - Abstract
A total of 13672 viruses, collected by World Health Organization recognised National Influenza Centres between May 2016 and May 2017, were assessed for neuraminidase inhibitor susceptibility by four WHO Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance Epidemiology and Control of Influenza. The 50% inhibitory concentration (IC 50 ) was determined for oseltamivir and zanamivir for all viruses, and for peramivir and laninamivir in a subset (n = 8457). Of the viruses tested, 94% were obtained from the Western Pacific, Americas and European WHO regions, while limited viruses were available from the Eastern Mediterranean, African and South East Asian regions. Reduced inhibition (RI) by one or more neuraminidase inhibitor was exhibited by 0.2% of viruses tested (n = 32). The frequency of viruses with RI has remained low since this global analysis began (2015/16: 0.8%, 2014/15: 0.5%; 2013/14: 1.9%; 2012/13: 0.6%) but 2016/17 has the lowest frequency observed to date. Analysis of 13581 neuraminidase sequences retrieved from public databases, of which 5243 sequences were from viruses not included in the phenotypic analyses, identified 58 further viruses (29 without phenotypic analyses) with amino acid substitutions associated with RI by at least one neuraminidase inhibitor. Bringing the total proportion to 0.5% (90/18915). This 2016/17 analysis demonstrates that neuraminidase inhibitors remain suitable for treatment and prophylaxis of influenza virus infections, but continued monitoring is important. An expansion of surveillance testing is paramount since several novel influenza antivirals are in late stage clinical trials with some resistance already having been identified. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.
- Author
-
Tilmanis, Danielle, van Baalen, Carel, Oh, Ding Yuan, Rossignol, Jean-Francois, and Hurt, Aeron C.
- Subjects
- *
INFLUENZA viruses , *METABOLITES , *ANTIPARASITIC agents , *INFLUENZA treatment , *HEMAGGLUTININ , *NEURAMINIDASE - Abstract
Nitazoxanide is a thiazolide compound that was originally developed as an anti-parasitic agent, but has recently been repurposed for the treatment of influenza virus infections. Thought to exert its anti-influenza activity via the inhibition of hemagglutinin maturation and intracellular trafficking in infected cells, the effectiveness of nitazoxanide in treating patients with non-complicated influenza is currently being assessed in phase III clinical trials. Here, we describe the susceptibility of 210 seasonal influenza viruses to tizoxanide, the active circulating metabolite of nitazoxanide. An optimised cell culture-based focus reduction assay was used to determine the susceptibility of A(H1N1)pdm09, A(H3N2), and influenza B viruses circulating in the southern hemisphere from the period March 2014 to August 2016. Tizoxanide showed potent in vitro antiviral activity against all influenza viruses tested, including neuraminidase inhibitor-resistant viruses, allowing the establishment of a baseline level of susceptibility for each subtype. Median EC 50 values (±IQR) of 0.48 μM (0.33–0.71), 0.62 μM (0.56–0.75), 0.66 μM (0.62–0.69), and 0.60 μM (0.51–0.67) were obtained for A(H1N1)pdm09, A(H3N2), B(Victoria lineage), and B(Yamagata lineage) influenza viruses respectively. There was no significant difference in the median baseline tizoxanide susceptibility for each influenza subtype tested. This is the first report on the susceptibility of circulating viruses to tizoxanide. The focus reduction assay format described is sensitive, robust, and less laborious than traditional cell based antiviral assays, making it highly suitable for the surveillance of tizoxanide susceptibility in circulating seasonal influenza viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
31. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016.
- Author
-
Gubareva, Larisa V., Besselaar, Terry G., Daniels, Rod S., Fry, Alicia, Gregory, Vicki, Huang, Weijuan, Hurt, Aeron C., Jorquera, Patricia A., Lackenby, Angie, Leang, Sook-Kwan, Lo, Janice, Pereyaslov, Dmitriy, Rebelo-de-Andrade, Helena, Siqueira, Marilda M., Takashita, Emi, Odagiri, Takato, Wang, Dayan, Zhang, Wenqing, and Meijer, Adam
- Subjects
- *
INFLUENZA viruses , *MICROBIAL sensitivity tests , *NEURAMINIDASE , *PUBLIC health surveillance - Abstract
Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) assessed antiviral susceptibility of 14,330 influenza A and B viruses collected by WHO-recognized National Influenza Centres (NICs) between May 2015 and May 2016. Neuraminidase (NA) inhibition assay was used to determine 50% inhibitory concentration (IC 50 ) data for NA inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. Furthermore, NA sequences from 13,484 influenza viruses were retrieved from public sequence databases and screened for amino acid substitutions (AAS) associated with reduced inhibition (RI) or highly reduced inhibition (HRI) by NAIs. Of the viruses tested by WHO CCs 93% were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 0.8% (n = 113) exhibited either RI or HRI by at least one of four NAIs. As in previous seasons, the most common NA AAS was H275Y in A(H1N1)pdm09 viruses, which confers HRI by oseltamivir and peramivir. Two A(H1N1)pdm09 viruses carried a rare NA AAS, S247R, shown in this study to confer RI/HRI by the four NAIs. The overall frequency of A(H1N1)pdm09 viruses containing NA AAS associated with RI/HRI was approximately 1.8% (125/6915), which is slightly higher than in the previous 2014-15 season (0.5%). Three B/Victoria-lineage viruses contained a new AAS, NA H134N, which conferred HRI by zanamivir and laninamivir, and borderline HRI by peramivir. A single B/Victoria-lineage virus harboured NA G104E, which was associated with HRI by all four NAIs. The overall frequency of RI/HRI phenotype among type B viruses was approximately 0.6% (43/7677), which is lower than that in the previous season. Overall, the vast majority (>99%) of the viruses tested by WHO CCs were susceptible to all four NAIs, showing normal inhibition (NI). Hence, NAIs remain the recommended antivirals for treatment of influenza virus infections. Nevertheless, our data indicate that it is prudent to continue drug susceptibility monitoring using both NAI assay and sequence analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. Quantifying relative within-host replication fitness in influenza virus competition experiments.
- Author
-
Petrie, Stephen M., Butler, Jeff, Barr, Ian G., McVernon, Jodie, Hurt, Aeron C., and McCaw, James M.
- Subjects
- *
INFLUENZA viruses , *DRUG resistance , *OSELTAMIVIR , *MIXED infections , *BIOLOGICAL systems - Abstract
Through accumulation of genetic mutations in the neuraminidase gene, the influenza virus can become resistant to antiviral drugs such as oseltamivir. Quantifying the fitness of emergent drug-resistant influenza viruses, relative to contemporary circulating viruses, provides valuable information to complement existing efforts in the surveillance of drug-resistance. We have previously developed a co-infection based method for the assessment of the relative in vivo fitness of two competing viruses. We have also introduced a model of within-host co-infection dynamics that enables relative within-host fitness to be quantified in these competitive-mixtures experiments. The model assumed that fitness differences between co-infecting strains were mediated by strain-dependent viral production rates from infected epithelial cells. Here we extend the model to enable a more complete exploration of biological processes that may differ between virus pairs and hence generate fitness differences. We use the extended model to re-analyse data from competitive-mixtures experiments that investigated the fitness of oseltamivir-resistant (OR) H1N1 pandemic 2009 (“H1N1pdm09”) viruses that emerged during a community outbreak in Australia in 2011. Results are consistent with those of our previous analysis, suggesting that the within-host replication fitness of these OR viruses is not compromised relative to that of related oseltamivir-susceptible (OS) strains, and that potentially permissive mutations in the neuraminidase gene (V241I and N369K) significantly enhance the fitness of H1N1pdm09 OR viruses. These results are consistent regardless of the hypothesised biological cause of fitness difference. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
33. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014.
- Author
-
Takashita, Emi, Meijer, Adam, Lackenby, Angie, Gubareva, Larisa, Rebelo-de-Andrade, Helena, Besselaar, Terry, Fry, Alicia, Gregory, Vicky, Leang, Sook-Kwan, Huang, Weijuan, Lo, Janice, Pereyaslov, Dmitriy, Siqueira, Marilda M., Wang, Dayan, Mak, Gannon C., Zhang, Wenqing, Daniels, Rod S., Hurt, Aeron C., and Tashiro, Masato
- Subjects
- *
INFLUENZA viruses , *NEURAMINIDASE , *EPIDEMIOLOGY , *OSELTAMIVIR , *RELENZA (Drug) , *THERAPEUTICS - Abstract
Four World Health Organization (WHO) Collaborating Centres for Reference and Research on Influenza and one WHO Collaborating Centre for the Surveillance, Epidemiology and Control of Influenza (WHO CCs) tested 10,641 viruses collected by WHO-recognized National Influenza Centres between May 2013 and May 2014 to determine 50% inhibitory concentration (IC 50 ) data for neuraminidase inhibitors (NAIs) oseltamivir, zanamivir, peramivir and laninamivir. In addition, neuraminidase (NA) sequence data, available from the WHO CCs and from sequence databases ( n = 3206), were screened for amino acid substitutions associated with reduced NAI susceptibility. Ninety-five per cent of the viruses tested by the WHO CCs were from three WHO regions: Western Pacific, the Americas and Europe. Approximately 2% ( n = 172) showed highly reduced inhibition (HRI) against at least one of the four NAIs, commonly oseltamivir, while 0.3% ( n = 32) showed reduced inhibition (RI). Those showing HRI were A(H1N1)pdm09 with NA H275Y ( n = 169), A(H3N2) with NA E119V ( n = 1), B/Victoria-lineage with NA E117G ( n = 1) and B/Yamagata-lineage with NA H273Y ( n = 1); amino acid position numbering is A subtype and B type specific. Although approximately 98% of circulating viruses tested during the 2013–2014 period were sensitive to all four NAIs, a large community cluster of A(H1N1)pdm09 viruses with the NA H275Y substitution from patients with no previous exposure to antivirals was detected in Hokkaido, Japan. Significant numbers of A(H1N1)pdm09 NA H275Y viruses were also detected in China and the United States: phylogenetic analyses showed that the Chinese viruses were similar to those from Japan, while the United States viruses clustered separately from those of the Hokkaido outbreak, indicative of multiple resistance-emergence events. Consequently, global surveillance of influenza antiviral susceptibility should be continued from a public health perspective. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
34. Substitutions Near the Receptor Binding Site Determine Major Antigenic Change During Influenza Virus Evolution.
- Author
-
Koel, Björn F., Burke, David F., Bestebroer, Theo M., der Vliet, Stefan van, Zondag, Gerben C. M., Vervaet, Gaby, Skepner, Eugene, Lewis, Nicola S., Spronken, Monique I. J., Russell, Colin A., Eropkin, Mikhail Y., Hurt, Aeron C., Barr, Ian G., de Jong, Jan C., Rimmelzwaan, Guus F., Osterhaus, Albert D. M. E., Fouchier, Ron A. M., and Smith, Derek J.
- Subjects
- *
INFLUENZA viruses , *BINDING sites , *VIRAL antigens , *HEMAGGLUTININ , *VIRAL antibodies , *AMINO acids - Abstract
The molecular basis of antigenic drift was determined for the hemagglutinin (HA) of human influenza A/H3N2 virus. From 1968 to 2003, antigenic change was caused mainly by single amino acid substitutions, which occurred at only seven positions in HA immediately adjacent to the receptor binding site. Most of these substitutions were involved in antigenic change more than once. Equivalent positions were responsible for the recent antigenic changes of influenza B and A/H1N1 viruses. Substitution of a single amino acid at one of these positions substantially changed the virus-specific antibody response in infected ferrets. These findings have potentially far-reaching consequences for understanding the evolutionary mechanisms that govern influenza viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
35. The Recent Establishment of North American H10 Lineage Influenza Viruses in Australian Wild Waterfowl and the Evolution of Australian Avian Influenza Viruses.
- Author
-
Vijaykrishna, Dhanasekaran, Yi-Mo Deng, Su, Yvonne C. F., Fourment, Mathieu, Iannello, Pina, Arzey, George G., Hansbro, Philip M., Edla Arzey, K., Kirkland, Peter D., Warner, Simone, O'Riley, Kim, Barr, Ian G., Smith, Gavin J. D., and Hurt, Aeron C.
- Subjects
- *
INFLUENZA viruses , *WATER birds , *AVIAN influenza A virus , *ANATIDAE , *HEMAGGLUTININ - Abstract
Influenza A H10N7 virus with a hemagglutinin gene of North American origin was detected in Australian chickens and poultry abattoir workers in New South Wales, Australia, in 2010 and in chickens in Queensland, Australia, on a mixed chicken and domestic duck farm in 2012. We investigated their genomic origins by sequencing full and partial genomes of H10 viruses isolated from wild aquatic birds and poultry in Australia and analyzed them with all available avian influenza virus sequences from Oceania and representative viruses from North America and Eurasia. Our analysis showed that the H10N7 viruses isolated from poultry were similar to those that have been circulating since 2009 in Australian aquatic birds and that their initial transmission into Australia occurred during 2007 and 2008. The H10 viruses that appear to have developed endemicity in Australian wild aquatic birds were derived from several viruses circulating in waterfowl along various flyways. Their hemagglutinin gene was derived from aquatic birds in the western states of the United States, whereas the neuraminidase was closely related to that from viruses previously detected in waterfowl in Japan. The remaining genes were derived from Eurasian avian influenza virus lineages. Our analysis of virological data spanning 40 years in Oceania indicates that the long-term evolutionary dynamics of avian influenza viruses in Australia may be determined by climatic changes. The introduction and long-term persistence of avian influenza virus lineages were observed during periods with increased rainfall, whereas bottlenecks and extinction were observed during phases of widespread decreases in rainfall. These results extend our understanding of factors affecting the dynamics of avian influenza and provide important considerations for surveillance and disease control strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
36. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
- Author
-
Tilmanis, Danielle, Koszalka, Paulina, Barr, Ian G., Rossignol, Jean-Francois, Mifsud, Edin, and Hurt, Aeron C.
- Subjects
- *
INFLUENZA viruses , *ANTIVIRAL agents , *DRUG resistance , *OSELTAMIVIR , *INFLUENZA , *AMINO acids - Abstract
A major limitation of the currently available influenza antivirals is the potential development of drug resistance. The adamantanes, neuraminidase inhibitors, and more recently polymerase inhibitors, have all been associated with the emergence of viral resistance in preclinical, clinical studies or in clinical use. As a result, host-targeted drugs that act on cellular proteins or functions have become an attractive option for influenza treatment as they are less likely to select for resistance. Nitazoxanide (NTZ) is a host-targeted antiviral that is currently in Phase III clinical trials for the treatment of influenza. In this study, we investigated the propensity for circulating influenza viruses to develop resistance to nitazoxanide in vitro by serially passaging viruses under selective pressure. Phenotypic and genotypic analysis of viruses passaged ten times in the presence of up to 20 μM tizoxanide (TIZ; the active metabolite of nitazoxanide) showed that none had a significant change in TIZ susceptibility, and amino acid substitutions arising that were unique to TIZ passaged viruses, did not alter TIZ susceptibility. Combination therapy, particularly utilising drugs with different mechanisms of action, is another option for combatting antiviral resistance, and while combination therapy has been shown to improve antiviral effects, the effect of reducing the emergence and selection of drug-resistant virus has been less widely investigated. Here we examined the use of TIZ in combination with oseltamivir, both in vitro and using the ferret model for influenza infection and found that the combination of the two drugs did not provide significant benefit in reducing the emergence or selection of oseltamivir-resistant virus. These in vitro findings suggest that clinical use of NTZ may be significantly less likely to select for resistance in circulating influenza viruses compared to virus-targeted antivirals, and although the combination of NTZ with oseltamivir did not reduce the emergence of oseltamivir-resistant virus in vitro or in vivo , combination therapy with NTZ and other newer classes of influenza antiviral drugs should be considered due to NTZ's higher host-based barrier to resistance. • Serial passaging was used to determine the propensity for influenza viruses to develop resistance to tizoxanide. • Tizoxanide selective pressure up to 20 μM did not result in virus populations with altered drug susceptibility. • Host-targeted Nitazoxanide has a high barrier to antiviral resistance. • Tizoxanide/oseltamivir combination therapy did not prevent the emergence or selection of oseltamivir resistant virus. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017–2018.
- Author
-
Takashita, Emi, Daniels, Rod S., Fujisaki, Seiichiro, Gregory, Vicki, Gubareva, Larisa V., Huang, Weiijuan, Hurt, Aeron C., Lackenby, Angie, Nguyen, Ha T., Pereyaslov, Dmitriy, Roe, Merryn, Samaan, Magdi, Subbarao, Kanta, Tse, Herman, Wang, Dayan, Yen, Hui-Ling, Zhang, Wenqing, and Meijer, Adam
- Subjects
- *
NEURAMINIDASE , *INFLUENZA viruses , *VIRUS inhibitors , *VIRUS diseases , *GLOBAL analysis (Mathematics) , *AMINO acids - Abstract
The global analysis of neuraminidase inhibitor (NAI) susceptibility of influenza viruses has been conducted since the 2012–13 period. In 2018 a novel cap-dependent endonuclease inhibitor, baloxavir, that targets polymerase acidic subunit (PA) was approved for the treatment of influenza virus infection in Japan and the United States. For this annual report, the susceptibilities of influenza viruses to NAIs and baloxavir were analyzed. A total of 15409 viruses, collected by World Health Organization (WHO) recognized National Influenza Centers and other laboratories between May 2017 and May 2018, were assessed for phenotypic NAI susceptibility by five WHO Collaborating Centers (CCs). The 50% inhibitory concentration (IC 50) was determined for oseltamivir, zanamivir, peramivir and laninamivir. Reduced inhibition (RI) or highly reduced inhibition (HRI) by one or more NAIs was exhibited by 0.8% of viruses tested (n = 122). The frequency of viruses with RI or HRI has remained low since this global analysis began (2012–13: 0.6%; 2013–14: 1.9%; 2014–15: 0.5%; 2015–16: 0.8%; 2016–17: 0.2%). PA gene sequence data, available from public databases (n = 13523), were screened for amino acid substitutions associated with reduced susceptibility to baloxavir (PA E23G/K/R, PA A36V, PA A37T, PA I38F/M/T/L, PA E119D, PA E199G): 11 (0.08%) viruses possessed such substitutions. Five of them were included in phenotypic baloxavir susceptibility analysis by two WHO CCs and IC 50 values were determined. The PA variant viruses showed 6–17-fold reduced susceptibility to baloxavir. Overall, in the 2017–18 period the frequency of circulating influenza viruses with reduced susceptibility to NAIs or baloxavir was low, but continued monitoring is important. • Influenza viruses collected worldwide were analyzed for susceptibilities to NA and PA inhibitors, May 2017–May 2018. • A total of 15,409 viruses were assessed for NA inhibitor phenotypic susceptibility. • A total of 13,523 PA sequences were screened for mutations associated with reduced PA inhibitor baloxavir susceptibility. • The frequency of viruses with reduced susceptibility to NA (0.8%) or PA (0.08%) inhibitors was low. • Global surveillance of influenza antiviral susceptibility should be continued. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses
- Author
-
Russell, Colin A., Jones, Terry C., Barr, Ian G., Cox, Nancy J., Garten, Rebecca J., Gregory, Vicky, Gust, Ian D., Hampson, Alan W., Hay, Alan J., Hurt, Aeron C., de Jong, Jan C., Kelso, Anne, Klimov, Alexander I., Kageyama, Tsutomu, Komadina, Naomi, Lapedes, Alan S., Lin, Yi P., Mosterin, Ana, Obuchi, Masatsugu, and Odagiri, Takato
- Subjects
- *
INFLUENZA viruses , *INFLUENZA vaccines , *PANDEMICS , *VIRUS diseases - Abstract
Abstract: Annual influenza epidemics in humans affect 5–15% of the population, causing an estimated half million deaths worldwide per year [Stohr K. Influenza—WHO cares. Lancet Infectious Diseases 2002;2(9):517]. The virus can infect this proportion of people year after year because the virus has an extensive capacity to evolve and thus evade the immune response. For example, since the influenza A(H3N2) subtype entered the human population in 1968 the A(H3N2) component of the influenza vaccine has had to be updated almost 30 times to track the evolution of the viruses and remain effective. The World Health Organization Global Influenza Surveillance Network (WHO GISN) tracks and analyzes the evolution and epidemiology of influenza viruses for the primary purpose of vaccine strain selection and to improve the strain selection process through studies aimed at better understanding virus evolution and epidemiology. Here we give an overview of the strain selection process and outline recent investigations into the global migration of seasonal influenza viruses. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.